Nasus Pharma Ltd. NSRX
2.85 USD -0.08 (-2.90%)
Nov 10, 2026, 2:50 PM EST
2.86 Day range 2.96
1.98 52-week range 9.50
- YTD
- -68.85%
- 1 year
- -62.00%
News
benzinga.com This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).
benzinga.com Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7 Maxim Group analyst Naz Rahman initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $7.
benzinga.com Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17)…
benzinga.com Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27 Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the
benzinga.com Nasus Pharma Announces NS003 Trial Demonstrates Preclinical Pharmacokinetic Profile Comparable To IV Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18 Citizens analyst Jason N. Butler maintains Nasus Pharma (AMEX:NSRX) with a Market Outperform and lowers the price target from $19 to $18.
benzinga.com Nasus Pharma Announces Phase 2 Results From NS002 Shows Improvements In Early Absorption Compared To EpiPen; Pivotal Trial Planned For !4 Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the filing of…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com What's Going On With Nasus Pharma Stock On Wednesday Nasus Pharma stock drops despite fast NS002 results beating EpiPen. Here's why shares are falling and what the data shows.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Nasus Pharma Stock Hits 52-Week Low - Here's Why Nasus Pharma (NSRX) hits a 52-week low despite positive Phase 2 data for its EpiPen rival. See why the stock is down 43% today.
benzinga.com Crude Oil Down 4%; Dollar Tree Earnings Top Views 
benzinga.com Dow Jumps Over 500 Points; NY Empire State Manufacturing Index Falls In March US stocks rise, Nasdaq gains 100 pts. Dow up 1.14%, Nasdaq up 1.38%, S&P 500 up 1.24%. Financial shares up 1.6%, energy stocks up 0.2%. NY Empire State Manufacturing Index declines to -0.2 in March.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Nasus Pharma's Topline Results From Phase 2 Study Of NS002 For Anaphylaxis Shows NS002 Achieved Significantly Faster And Higher Early Epinephrine Absorption Compared To Intramuscular Epipen Autoinjector NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4%…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Nasus Pharma To Present Topline Analysis From Its Phase 2 Repeated Dose Clinical Study Of NS002 Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Nasus Pharma Announces Interim Results From Phase 2 Clinical Study Of NS002, Investigational Intranasal Epinephrine Powder Formulation For Treatment Of Anaphylaxis Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen®91% of study participants achieved the 100 pg/ml plasma threshold at…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Citizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of $19 Citizens analyst Jason Butler initiates coverage on Nasus Pharma (AMEX:NSRX) with a Market Outperform rating and announces Price Target of $19.
- benzinga.com Nasus Pharma Appoints Eyal Rubin As EVP And CFO Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency…
- benzinga.com Nasus Pharma Initiates Phase 2 Clinical Study To Evaluate NS002 Investigational Intranasal Epinephrine Powder Formulation With Dosing Of First Patient To Treat Anaphylaxis Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical…
- benzinga.com Nasus Pharma Announces Health Canada Has Issued A No-Objection Letter Allowing The Company To Proceed With A Phase 2 Clinical Trial Of NS002, Its Intranasal Epinephrine Powder Being Developed For The Treatment Of Anaphylaxis Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22 Laidlaw & Co. analyst Yale Jen initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $22.
- benzinga.com Nasus Pharma Prices $10M Initial Public Offering Of 1.25M Ordinary Shares At $8.00 Per Share The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional…